A Validated Enantioselective Assay for the Determination of Ibuprofen in Human Plasma Using Ultra Performance Liquid Chromatography with Tandem Mass Spectrometry (UPLC-MS/MS)

András Szeitz, Andrea Nicole Edginton, Henry Tao Peng, Bob Cheung, Kenneth Wayne Riggs

.

DOI: 10.4236/ajac.2010.12007                

Abstract

A modified ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed and validated for the quantitation of ibuprofen enantiomers in human plasma. Ibuprofen and flurbiprofen (internal standard) were extracted from human plasma at acidic pH, using a single-step liquid-liquid extraction with methyl-tert-butyl ether. The enantiomers of ibuprofen and flurbiprofen were derivatized to yield the corresponding diastereomers. Chromatographic separation was achieved using a phenyl column with a run time of 20 min. (R)- and (S)-ibuprofen were quantitated at the multiple reaction monitoring (MRM) transition of m/z 360.2 ? 232.1, and (R)- and (S)-flurbiprofen were monitored at the MRM transition of m/z 398.3 ? 270.1. The method was validated for accuracy, precision, linearity, range, limit of quantitation (LOQ), limit of detection (LOD), selectivity, absolute recovery, matrix effect, dilution integrity, and evaluation of carry-over. Accuracy for (R)-ibuprofen ranged between –11.8% and 11.2%, and for (S)-ibuprofen between –8.6% and –0.3%. Precision for (R)-ibuprofen was ≤ 11.2%, and for (S)-ibuprofen ≤ 7.0%. The calibration curves were weighted (1/X2, n = 7) and were linear with r2 for (R)-ibuprofen ≥ 0.988 and for (S)-ibuprofen ≥ 0.990. The range of the method was 50 to 5000 ng/mL with the LOQ of 50 ng/mL, and LOD of 1 ng/mL, for (R)- and (S)-ibuprofen requiring 100 µL of sample. The method was applied successfully to a pharmacokinetic study with the administration of a single oral dose of ibuprofen capsules to human subjects.

Keywords

Ibuprofen Enantiomers, UPLC-MS/MS, Human Plasma, Method Validation, Pharmacokinetics

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	R. D. Knihinicki, K. M. Williams and R. O. Day, “Chiral Inversion of 2-Arylpropionic Acid Non-Steroidal Anti- Inflammatory Drugs—I. In Vitro Studies of Ibuprofen and Flurbiprofen,” Biochemical Pharmacology, Vol. 38, No. 24, December 1989, pp. 4389-4395.
[2]	S. M. Sanins, W. J. Adams, D. G. Kaiser, G. W. Halstead, J. Hosley, H. Barnes and T. A. Baillie, “Mechanistic Studies on the Metabolic Chiral Inversion of R-Ibuprofen in the Rat,” Drug Metabolism and Disposition, Vol. 19, No. 2, March-April 1991, pp. 405-410.
[3]	S. Fournel and J. Caldwell, “Metabolic Chiral Inversion of 2-Phenylpropionic Acid in Rat, Mouse and Rabbit,” Biochemical Pharmacology, Vol. 35, No. 23, December 1986, pp. 4153-4159.
[4]	J. Caldwell, A. J. Hull and S. Fournel-Gigleux, “The Metabolic Chiral Inversion and Dispositional Enantioselectivity of the 2-Arylpropionic Acids and their Biological Consequences,” Biochemical Pharmacology, Vol. 37, No. 1, January 1988, pp. 105-114.
[5]	D. G. Kaiser, G. J. Van Giessen, R. J. Reischer and W. J. Wechter, “Isomeric Inversion of Ibuprofen (R)-Enantiomer in Humans,” Journal of Pharmaceutical Sciences, Vol. 65, No. 2, February 1976, pp. 269-273.
[6]	T. A. Baillie, W. J. Adams, D. G. Kaiser, L. S. Olanoff, G. W. Halstead, H. Harpootlian and G. J. Van Giessen, “Mechanistic Studies of the Metabolic Chiral Inversion of (R)-Ibuprofen in Humans,” Journal of Pharmacology and Experimental Therapeutics, Vol. 249, No. 2, May 1989, pp. 517-523.
[7]	S. S. Adams, P. Bresloff and C. G. Mason, “Pharmacological Differences Between Optical Isomers of Ibuprofen: Evidence for Metabolic Inversion of the (–)-Isomer,” Journal of Pharmacy and Pharmacology, Vol. 28, No. 3, March 1976, pp. 256-257.
[8]	A. J. Hutt and J. Caldwell, “The Metabolic Chiral Inversion of 2-Aryl Propionic Acids—A Novel Route with Pharmacological Consequences,” Journal of Pharmacy and Pharmacology, Vol. 35, No. 11, November 1983, pp. 693-704.
[9]	A. J. Hutt and J. Caldwell, “The Importance of Stereochemistry in the Clinical Pharmacokinetics of the 2- Arylpropionic Acid Non-Steroidal Anti-Inflammatory Drugs,” Clinical Pharmacokinetics, Vol. 9, No. 4, July- August 1984, pp. 371-373.
[10]	S. C. Tan, B. K. Patel, S. H. D. Jackson, C. G. Swift, and J. Hutt, “Stereoselectivity of Ibuprofen Metabolism and Pharmacokinetics Following the Administration of the Racemate to Healthy Volunteers,” Xenobiotica, Vol. 32, No. 8, August 2002, pp. 683-697.
[11]	H. Hao, G. Wang and J. Sun, “Enantioselective Pharmacokinetics of Ibuprofen and Involved Mechanisms,” Drug Metabolism Reviews, Vol. 73, No. 1, January 2005, pp. 215-234.
[12]	E. J. Lee, K. Williams, R. Day, G. Graham and D. Champion, “Stereoselective Disposition of Ibuprofen Enantiomers in Man,” British Journal of Clinical Pharmacology, Vol. 19, No. 5, May 1985, pp. 669-674.
[13]	S. C. Tan, B. K. Patel, S. H. Jackson, C. G. Swift and A. J. Hutt, “Influence of Age on the Enantiomeric Disposition of Ibuprofen in Healthy Volunteers,” British Journal of Clinical Pharmacology, Vol. 55, No. 6, June 2003, pp. 579-587.
[14]	G. F. Lockwood, K. S. Albert, G. J. Szpunar and J. G. Wagner, “Pharmacokinetics of Ibuprofen in Man—III: Plasma Protein Binding,” Journal of Pharmacokinetics & Biopharmaceutics, Vol. 11, No. 5, October 1983, pp. 469-482.
[15]	J. K. Paliwal, D. E Smith, S. R Cox, R. R Berardi, V. A. Dunn-Kucharski and G. H. Elta, “Stereoselective, Competitive, and Nonlinear Plasma Protein Binding of Ibuprofen Enantiomers as Determined in Vivo in Healthy Subjects,” Journal of Pharmacokinetics and Biopharmaceutics, Vol. 21, No. 2, April 1993, pp. 145-161.
[16]	J. C. Nielsen, P. Bjerring, L. Arendt-Nielsen and K.-J. Petterson, “A Double-Blind, Placebo Controlled, Cross- over Comparison of the Analgesic Effect of Ibuprofen 400 Mg and 800 Mg on Laser-Induced Pain,” British Journal of Clinical Pharmacology, Vol. 30, No. 5, November 1990, pp. 711-715.
[17]	P. Camilleri and C. Dyke, “Effect of 2H2O on the Resolution of the Optical Isomers of Ibuprofen on an Α1-Acid Glycoprotein Column,” Journal of Chromatography A, Vol. 518, June 1990, pp. 277-281.
[18]	S. Menzel-Soglowek, G. Geisslinger and K. Brune, “Stereoselective High-Performance Liquid Chromatographic Determination of Ketoprofen, Ibuprofen and Fenoprofen in Plasma Using a Chiral Alpha 1-Acid Glycoprotein Column,” Journal of Chromatography A, Vol. 532, No. 2, November 1990, pp. 295-303.
[19]	K. J. Pettersson and A. Olsson, “Liquid Chromatographic Determination of The Enantiomers of Ibuprofen in Plasma Using a Chiral AGP Column,” Journal of Chromatography A, Vol. 563, No. 2, February 1991, pp. 414-418.
[20]	W. Naidong and J. W. Lee, “Development and Validation of a Liquid Chromatographic Method for the Quantitation of Ibuprofen Enantiomers in Human Plasma,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 12, No. 4, April 1994, pp. 551-556.
[21]	H. Y. Aboul-Enein, A. Van Overbeke, G. Vander Weken, W. Baeyens, H. Oda, P. Deprez and A. De Kruif, “HPLC on Chiralcel OJ-R for Enantiomer Separation and Analysis of Ketoprofen, from Horse Plasma, as the 9-Aminophenanthrene Derivative,” Journal of Pharmacy and Pharmacology, Vol. 50, No. 3, March 1998, pp. 291-296.
[22]	K. Tachibana and A. Ohnishi, “Reversed-Phase Liquid Chromatographic Separation of Enantiomers on Polysaccharide Type Chiral Stationary Phases,” Journal of Chro- matography A, Vol. 906, No. 1-2, January 2001, pp. 127-154.
[23]	X. W. Teng, S.W. Wang and N. M. Davies, “Stereospecific High-Performance Liquid Chromatographic Analysis of Ibuprofen in Rat Serum,” Journal of Chromatography B, Vol. 796, No. 2, November 2003, pp. 225-231.
[24]	A. Reddy, M. Hashim, Z. Wang. L. Penn, C. J. Stankovic, D. Burdette, N. Surendran and H. Cai, “A Novel Method for Assessing Inhibition of Ibuprofen Chiral Inversion and its Application in Drug Discovery,” International Journal of Pharmaceutics, Vol. 335, No. 1-2, April 2007, pp. 63-69.
[25]	P. S. Bonato, M. P. Del Lama and R. Carvalho, “Enantioselective Determination of Ibuprofen in Plasma by High-Performance Liquid Chromatography-Electrospray Mass Spectrometry,” Journal of Chromatography B, Vol. 796, No. 2, November 2003, pp. 413-420.
[26]	E. J. D. Lee, K. M. Williams, G. G. Graham, R. O. Day, and G. D. Champion, “Liquid Chromatographic Determination and Plasma Concentration Profile of Optical Isomers of Ibuprofen in Humans,” Journal of Pharmaceutical Sciences, Vol. 73, No. 11, November 1984, pp. 1542-1544.
[27]	R. Mehvar, F. JamaII and F. M. Pasutto, “Liquid- Chromatographic Assay of Ibuprofen Enantiomers in Plasma,” Clinical Chemistry, Vol. 34, No. 3, March 1988, pp. 493-496.
[28]	C. H. Lemko, G. Caille and R. T. Foster, “Stereospecific High-Performance Liquid Chromatographic Assay of Ibuprofen: Improved Sensitivity and Sample Processing Efficiency,” Journal of Chromatography A, Vol. 619, No. 2, September 1993, pp. 330-335.
[29]	S. C. Tan, S. H. D Jackson, C. G Swift and A. J. Hutt, “Enantiospecific Analysis of Ibuprofen by High Performance Liquid Chromatography: Determination of Free and Total Drug Enantiomer Concentrations in Serum and Urine,” Chromatographia, Vol. 46, No. 1-2, July 1997, pp. 23-32.
[30]	M. J. Hilton and K. V. Thomas, “Determination of Selected Human Pharmaceutical Compounds in Effluent and Surface Water Samples by High-Performance Liquid Chromatography-Electrospray Tandem Mass Spectrometry,” Journal of Chromatography A, Vol. 1015, No. 1-2, October 2003, pp. 129-141.
[31]	R. Leverence, M. J. Avery, O. Kavetskaia, H. Bi, C. E. Hop and A. I. Gusev, “Signal Suppression/Enhancement in HPLC-ESI-MS/MS from Concomitant Medications,” Biomedical Chromatography, Vol. 21, No. 11, November 2007, pp. 1143-1150.
[32]	S. Y. Chang, W. Li, S. C. Traeger, B. Wang, D. Cui, H. Zhang, B. Wen and A.D. Rodrigues, “Confirmation that Cytochrome P450 2C8 (CYP2C8) Plays a Minor Role in (S)-(+)- and (R)-(-)-Ibuprofen Hydroxylation in Vitro,” Drug Metabolism and Disposition, Vol. 36, No. 12, December 2008, pp. 2513-2522.
[33]	G. D. Mendes, F. D. Mendes, C. C. Domingues, R. A de Oliveira, M. A. da Silva, L. S. Chen, J. O. Ilha, C. E. Fernandes and G. De Nucci, “Comparative Bioavailability of Three Ibuprofen Formulations in Healthy Human Volunteers,” International Journal of Clinical Pharmacology and Therapeutics, Vol. 46, No. 6, June 2008, pp. 309- 318.
[34]	P. Seideman, F. Lohrer, G. G. Graham, M. W. Duncan, K. M. Williams and R. O. Day, “The Stereoselective Disposition of the Enantiomers of Ibuprofen in Blood, Blister and Synovial Fluid,” British Journal of Clinical Pharmacology, Vol. 38, No. 3, September 1994, pp. 221-227.
[35]	B. A. Way, T. R. Wilhite, C. H. Smith and M. Landt, “Measurement of Plasma Ibuprofen by Gas Chromatography-Mass Spectrometry,” Journal of Clinical Laboratory Analysis, Vol. 11, No. 6, April 1997, pp. 336-339.
[36]	á. Seb?k, A. Vasanits-Zsigrai, Gy. Palkó, Gy. Záray and I. Molnár-Perl, “Identification and Quantification of Ibuprofen, Naproxen, Ketoprofen and Diclofenac Present in Waste-Waters, as their Trimethylsilyl Derivatives, by Gas Chromatography Mass Spectrometry,” Talanta, Vol. 76, No. 3, July 2008, pp. 642-650.